Risperidone Half-Life in a Patient Taking Paroxetine

This case report further establishes the inhibitory effects of paroxetine on risperidone (R) metabolism in a patient whose R was discontinued due to side effects. Baseline through levels in ng/ml were 33 for R, 9 for 9-hydroxyrisperidone (9-OHR) and 42 for the total moiety. The fourth morning after R discontinuation, levels were 4 for R, 1 for 9-OHR and 5 for the total moiety. The estimated half-lives were 23.8 hours for R, 22.8 hours for 9-OHR and 23.5 hours for the total moiety.

References

• 1 Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology (letter).  J Clin Psychiatry. 1999;  60 55-56
• 2 Alfaro C L, Lam Y W, Simpson J. et al . CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.  J Clin Psychopharmacol. 1999;  19 155-163
• 3 Balant-Gorgia A E, Gex-Fabry M, Genet C. et al . Therapeutic drug monitoring of risperidone using a new rapid HPLC method: reappraisal of interindividual variability factors.  Ther Drug Monitior. 1999;  21 105-115
• 4 Baumann P, Hiemke C, Uhlrich S. et al . The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-256
• 5 Berecz R, LLerena A, de la Rubia A. et al . Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.  Pharmacopsychiatry. 2002;  35 231-234
• 6 Bork J, Rogers T, Wedlund P. et al . A pilot study of risperidone metabolism: The role of cytochrome P450 2D6 and 3A.  J Clin Psychiatry. 1999;  60 469-476
• 7 Chou W H, Yan F X, Robbins-Weilert D K. et al . Comparison of two CYP2D6 genotyping methods and assessments of genotype-phenotype relationships.  Clin Chem. 2003;  49 542-551
• 8 de Leon J, Susce M T, Pan R M. et al . The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.  J Clin Psychiatry. 2005;  66 15-27
• 9 Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics.  J Clin Psychiatry. 1996;  57 (Suppl 11) 12-25
• 10 Guzey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer (letter).  J Clin Psychiatry. 2000;  61 600-601
• 11 Huang M, Van Peer A, Woestenborghs R. et al . Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.  Clin Pharmacol Ther. 1993;  54 257-268
• 12 Kohnke M D, Griese E U, Stosser D. et al . Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.  Pharmacopsychiatry. 2002;  35 116-118
• 13 Martin K, Begaud B, Verdoux H. et al . Patterns of risperidone prescription: a utilization study in south-west France.  Acta Psychiatr Scand. 2004;  109 202-206
• 14 Megens A AHP, Awoteurs F HL, Schtte A. et al . Survey on pharmacodynamics of the new antipsychotic risperidone.  Psychopharmacol. 1994;  114 9-23
• 15 O’Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression (letter).  J Clin Psychopharmacol. 1998;  18 89-91
• 16 Spina E, Avenoso A, Facciola G. et al . Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.  Ther Drug Monit. 2001;  23 223-227
• 17 Wang J S, Ruan Y, Taylor R M. et al . The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by p-glycoprotein.  Int J Neuropsychopharmacology. 2004;  7 415-419
• 18 Wright J G, Boddy A V. All half-lives are wrong, but some half-lives are useful.  Clin Pharmacokinet. 2001;  40 237-244